Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other research analysts have also issued reports about the stock. Stephens boosted their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. HC Wainwright boosted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, Royal Bank Of Canada cut their target price on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.20.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $1.37 on Friday. The stock has a market capitalization of $85.30 million, a P/E ratio of -0.86 and a beta of 1.45. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.55. The company’s fifty day moving average is $1.49 and its two-hundred day moving average is $2.48.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PYXS. XTX Topco Ltd boosted its stake in shares of Pyxis Oncology by 1,533.0% during the 4th quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after acquiring an additional 271,334 shares in the last quarter. Toronto Dominion Bank purchased a new position in Pyxis Oncology in the 4th quarter valued at approximately $86,000. Quadrature Capital Ltd purchased a new position in Pyxis Oncology in the 4th quarter valued at approximately $116,000. Maia Wealth LLC acquired a new position in Pyxis Oncology during the fourth quarter worth $25,000. Finally, Engineers Gate Manager LP acquired a new position in Pyxis Oncology during the fourth quarter worth $26,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.